Drug intelligence / Profile preview

Cetilar

Development stage
Unknown
Lead developer
Pharmanutra
Modality
Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration
Topical, Transdermal
01

Overview

Cetilar is a topical cream formulated primarily with cetylated fatty acids (CFAs) and menthol, designed for the relief of joint, muscle, and tendon pain. Its mechanism of action is based on the ability of CFAs—fatty acids esterified with cetyl alcohol—to penetrate the skin barrier, stabilize and lubricate cell membranes, reduce inflammation, and support recovery in musculoskeletal tissues. The product also contains menthol (1.4%), which provides a topical analgesic effect by activating cold-sensitive receptors in the skin to temporarily relieve minor aches and pains. Cetilar is indicated for use in therapeutic massage to improve joint function, mobility after injury or surgery (including osteoarthritis), rehabilitation following inflammatory or traumatic events, as well as sports injuries[1][2][3][4][5][7][9]. It is developed by PharmaNutra S.p.A., an Italian company specializing in nutritional supplements and medical devices[6][8][10].

Brand names
Cetilar
02

Targets

TRPM8 (Transient receptor potential cation channel subfamily M member 8)

Beyond the preview

Go deeper on Cetilar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cetilar.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call